Maginjectable (Magnesium Pidolate)

Magnesium pidolate, the active ingredient in Maginjectable, is a magnesium supplement presented as a parenteral preparation for intramuscular and intravenous use. It is employed to correct magnesium deficiency and to replace electrolytes in patients who require rapid repletion, such as those with hypomagnesemia or postoperative electrolyte loss.

GNH USA supplies Maginjectable as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Maginjectable provides magnesium ions for conditions where electrolyte balance is compromised.

- Magnesium deficiency: restores normal magnesium levels and supports enzymatic functions. - Hypomagnesemia: rapidly corrects low serum magnesium in acute care settings. - Electrolyte replacement: assists in maintaining overall electrolyte homeostasis during surgery or critical illness.

Adverse reactions may occur with parenteral magnesium administration.

Common Side Effects: - Flushing or warmth at the injection site. - Mild hypotension. - Nausea or transient vomiting. - Headache. - Dizziness. - Localized pain or irritation.

Serious or Rare Side Effects: - Severe hypotension or cardiovascular collapse. - Respiratory depression. - Cardiac arrhythmias. - Hypermagnesemia with neuromuscular weakness. - Allergic reactions such as rash or anaphylaxis. - Injection site necrosis.

When using Maginjectable, consider the following safety measures.

- Renal impairment: monitor serum magnesium and adjust dosing. - Cardiac disease: observe for arrhythmias during infusion. - Concomitant calcium therapy: avoid simultaneous high‑dose calcium to prevent antagonism. - Pregnancy and lactation: use only if clearly needed and prescribed. - Pediatric patients: dose must be individualized by a qualified clinician. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Maginjectable may interact with several medications.

Major Interactions (Avoid): - Calcium channel blockers: additive effects on cardiac conduction. - Neuromuscular blocking agents: enhanced muscle relaxation. - Certain antibiotics (e.g., aminoglycosides): increased risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase magnesium loss, requiring monitoring. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Bisphosphonates: separate administration by at least 30 minutes.